Clinical Trial 20010

Study Title

IRONMAN: International Registry for Men with Advanced Prostate Cancer

Summary

The purpose of this study is to learn more about prostate cancer and to describe the use of different therapies for advanced prostate cancer internationally; to describe specific treatment patterns and whether they are associated with differences in outcomes such as hospitalizations; to identify associations between treatment sequences or combinations and overall survival; to define the patient experience of men with advanced prostate cancer and identify unmet needs in their treatment; and to identify clinical and molecular disease subtypes that may predict for a reduction in cancer from individual treatments, combinations, or sequences.

Objective

The IRONMAN Registry investigators intend to create an international, population-based, prospective registry of minimum 5,000 men with advanced prostate cancer. Target accrual number and number of participating sites are subject to change based on accrual, funding, and interest in participation by other international sites. The IRONMAN Registry aims to collect detailed clinical, epidemiological and biological information about these patients at study enrollment and to follow them prospectively with the following objectives: 1. To describe the practice patterns of therapeutic agents for treatment of advanced prostate cancer internationally; 2. To assess whether specific treatment patterns are associated with clinically significant adverse events, and evaluate potential interactions with concomitant medications or demographic factors; 3. To identify associations between treatment sequences or combinations and OS; 4. To define the patient experience of men with advanced prostate cancer and identify unmet needs in their treatment; 5. To identify clinical and molecular disease subtypes that predict response to individual treatments, combinations, or sequences.